Page 187 - 2019_02-Haematologica-web

Tandem transplantation for multiple myeloma
relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma. Bone Marrow Transplant. 2012;47(6):831-837.
50. Lonial S, Boise LH, Kaufman J. How I treat high-risk myeloma. Blood. 2015;126(13): 1536-1543.
51. Sobh M, Michallet M, Gahrton G, et al. Allogeneic hematopoietic cell transplanta- tion for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party. Leukemia. 2016;30(10):2047-2054.
52. Caballero-Velazquez T, Lopez-Corral L, Encinas C, et al. Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients. Br J Haematol. 2013;162(4):474-482.
53. Green DJ, Maloney DG, Storer BE, et al. Tandem autologous/allogeneic hematopoi- etic cell transplantation with bortezomib maintenance therapy for high-risk myelo- ma. Blood Adv. 2017;1(24):2247-2256.
54. Kneppers E, van der HB, Kersten MJ, et al. Lenalidomide maintenance after nonmye- loablative allogeneic stem cell transplanta- tion in multiple myeloma is not feasible: results of the HOVON 76 Trial. Blood. 2011;118(9):2413-2419.
55. Alsina M, Becker PS, Zhong X, et al. Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation. Biol
Blood Marrow Transplant. 2014;20(8):
1183-1189.
56. Kroger N, Zabelina T, Klyuchnikov E, et al.
Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients. Bone Marrow Transplant. 2013;48(3):403-407.
57. Giaccone L, Evangelista A, Patriarca F, et al. Impact of new drugs on the long-term fol- low-up of upfront tandem autograft-allo- graft in multiple myeloma. Biol Blood Marrow Transplant. 2018;24(1):189-193.
58. Htut M, D'Souza A, Krishnan A, et al. Autologous/allogeneic hematopoietic cell transplantation versus tandem autologous transplantation for multiple myeloma: Comparison of long-term postrelapse sur- vival. Biol Blood Marrow Transplant. 2018;24(3):478-485.
59. Walker BA, Boyle EM, Wardell CP, et al. Mutational spectrum, copy number changes, and outcome: Results of a sequencing study of patients with newly diagnosed myeloma. J Clin Oncol. 2015;33(33):3911-3920.
60. Thanendrarajan S, Tian E, Qu P, et al. The level of deletion 17p and bi-allelic inactiva- tion of TP53 has a significant impact on clinical outcome in multiple myeloma. Haematologica. 2017;102(9):e364-e367.
61. Kroger N, Badbaran A, Zabelina T, et al. Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplanta-
tion in patients with multiple myeloma. Biol Blood Marrow Transplant. 2013;19(3): 398-404.
62. Roos-Weil D, Moreau P, Avet-Loiseau H, et al. Impact of genetic abnormalities after allogeneic stem cell transplantation in mul- tiple myeloma: a report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Haematologica. 2011;96(10):1504-1511.
63. Rasche L, Rollig C, Stuhler G, et al. Allogeneic hematopoietic cell transplanta- tion in multiple myeloma: Focus on longi- tudinal assessment of donor chimerism, extramedullary disease, and high-risk cyto- genetic features. Biol Blood Marrow Transplant. 2016;22(11):1988-1996.
64. Avet-Loiseau H, Leleu X, Roussel M, et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol. 2010;28(30):4630- 4634.
65. Gay F, Engelhardt M, Terpos E, et al. From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspec- tives. Haematologica. 2018;103(2):197-211.
66. Garfall AL, Maus MV, Hwang WT, et al. Chimeric antigen receptor T cells against CD19 for multiple myeloma. N Engl J Med. 2015;373(11):1040-1047.
67. Mikkilineni L, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for multi- ple myeloma. Blood. 2017;130(24):2594- 2602.
haematologica | 2019; 104(2)
391